Skip to main content
SpringerLink
Log in

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474

    Article  PubMed  Google Scholar 

  2. Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O’Brien S, Keating MJ, Freireich EJ, Estey EH (1996) Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 10:964–969

    PubMed  CAS  Google Scholar 

  3. McHayleh W, Sehgal R, Redner RL, Raptis A, Agha M, Natale J, Luong TM, Schlesselman JJ, Foon KA, Boyiadzis M (2009) Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin. Leuk Lymphoma 50:1848–1853

    Article  PubMed  CAS  Google Scholar 

  4. Stasi R (2008) Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther 8:527–540

    Article  PubMed  CAS  Google Scholar 

  5. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490–1496

    PubMed  CAS  Google Scholar 

  6. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442–1452

    Article  PubMed  CAS  Google Scholar 

  7. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR (2009) Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:326–327

    Google Scholar 

  8. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, 5150 Center Avenue, Suite 565, Pittsburgh, PA, 15232, USA

    Michael Boyiadzis, Robert L. Redner, Anastasios Raptis, Jing-Zhou Hou, Mounzer Agha & Kenneth A. Foon

Authors
  1. Michael Boyiadzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Redner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anastasios Raptis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing-Zhou Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mounzer Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth A. Foon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Boyiadzis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyiadzis, M., Redner, R.L., Raptis, A. et al. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy. Ann Hematol 90, 733–735 (2011). https://doi.org/10.1007/s00277-010-1076-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1076-0

Keywords

Search

Navigation